What question did this study set out to answer?

To explore the molecular characteristics of lenalidomide-associated B-ALL and the role of IDH2 mutations and IKAROS loss in its development.

March 15, 2026Blood

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

View Full Paper

Ask AI

Bookmark

Authors

JHJohanna HornsUniversity Hospital Schleswig-Holstein TBThomas BederUniversity Hospital Schleswig-Holstein AKAxel KünstnerUniversity of Lübeck

Discussion

Member takes

Implication

Comprehensive analysis reveals IDH2 mutations and IKAROS loss contribute to B-ALL after lenalidomide, suggesting significant implications for treatment outcomes.

Key Points

To explore the molecular characteristics of lenalidomide-associated B-ALL and the role of IDH2 mutations and IKAROS loss in its development.
Molecular characterization of 57 patients with lenalidomide-associated B-ALL
Identification of mutational subgroups: TP53mt, IDH2mt, and others
Fluorescence-activated cell sorting and single-cell RNA sequencing for detecting IDH2 mutations
Transcriptomic and DNA methylation analyses for gene expression profiling.
IDH2 mutations (R140Q) found in 23% of LenB-ALL cases, significantly higher than in primary B-ALL (p<0.001)
IKZF1 deletions observed in 54% of IDH2mt LenB-ALL cases
IDH2 mutations persisted during MRD-negative remission
Distinct gene expression profile and hypermethylation phenotype characterized IDH2mt LenB-ALL.

Cite This Study

Horns et al. (2026) studied this question.

synapsesocial.com/papers/69b64d48b42794e3e660e1d0 https://doi.org/10.1182/blood.2025031047

View Full Paper

Ask AI

Bookmark

Implication

Comprehensive analysis reveals IDH2 mutations and IKAROS loss contribute to B-ALL after lenalidomide, suggesting significant implications for treatment outcomes.

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider